ImmunoCellular Therapeutics, Ltd. (IMUC)

Home > Quotes > IMUC

IMUC

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List

Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.

Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols

Symbol Lookup

Community Home
Join the NASDAQ Community today and get free, instant access to portfolios, stock ratings, real-time alerts, and more!
Join Today
Already a member?

Save stocks for next time

| Sponsored

News

Price
Charts

Trade
History

Annual
Report

Earnings
Report Date

Dynamic quotes: Off

1 Year Target:	7
Today's High/Low:	$ 2.59 / $ 2.50
Share Volume:	352,469
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume.	563,505
Previous Close:	$ 2.56
52 Week High /Low:	$ 4 / $ 1.51
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.	134,457,632
P/E Ratio:	NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year.	NE
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS.	$ -0.27
Annualized dividend	N/A
Ex Dividend Date	N/A
Dividend Payment Date	N/A
Current Yield	0 %
Beta	2.24

Intraday Chart

5d | 1m | 6m | 12m | More Charting

Company Description (as filed with the SEC)

ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an emerging approach to treating cancer in which a patient’s own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. Unlike many other cancer immunotherapies, which only target a single cancer antigen, our technology can elicit an immune response against several antigens. Our cancer immunotherapies are also distinguished by the fact that they target cancer stem cells (CSCs), which are the primary drivers of tumor growth and disease recurrence. Our most advanced product candidate is in Phase II development, and we have a portfolio of potential therapeutic immunotherapies using our proprietary approach to treating cancer. ... More ...